Skip to main content

Table 3 Uni- and multivariate analysis of factors associated with transplantation outcomes (n = 208)

From: Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

CovariateUnivariate analysisMultivariate analysis
HR95% CIP valueHR95% CIP value
Neutrophil engraftment
 CD34 cell infused (less vs. higher than median)0.7760.589–1.0210.0700.7490.567–0.9880.041
 Transplant modality (Haplo-SCT vs. MSDT)1.2750.899–1.8090.173   
Platelet engraftment
 CD34 cell infused (less vs. higher than median)0.6480.490–0.8570.0020.6710.506–0.8890.006
 Transplant modality (Haplo-SCT vs. MSDT)0.3880.269–0.561< 0.0010.4010.227–0.581< 0.001
Acute GVHD grades II–IV
 Disease status (≥ CR2 vs. CR1)2.4641.333–4.5570.0042.4681.330–4.5780.004
 Transplant modality (Haplo-SCT vs. MSDT)1.0810.502–2.3250.842   
Total chronic GVHD
 Time from diagnosis to transplant1.0111.000–1.0220.0531.0111.000–1.0220.050
 Transplant modality (Haplo-SCT vs. MSDT)0.9490.548–1.6410.850   
MRD positive after transplantation
 Disease status (≥ CR2 vs. CR1)1.6900.943–3.0310.078   
 Levels of pre-transplantation MRD1.2431.014–1.5230.0361.2811.043–1.5720.014
 Transplant modality (Haplo-SCT vs. MSDT)0.5260.301–0.9210.0240.4920.280–0.8660.018
Relapse
 Disease status (≥ CR2 vs. CR1)2.3561.343–4.1340.0032.5281.357–4.7070.003
 Diagnosis  0.037  0.002
  T-ALL2.7571.235–6.1570.0134.3561.814–10.4600.001
  PH negative B-ALL1.3790.710–2.6780.3431.3680.690–2.7130.370
  PH positive B-ALL1.0  1.0  
 Levels of pre-transplantation MRD2.2041.267–3.8350.0051.3201.060–1.6420.013
 Chronic GVHD (yes vs. no)0.4750.263–0.8590.0140.3370.181–0.6280.001
 Post-transplantation MRD2.1681.283–3.6640.0042.1491.253–3.6850.005
 Transplant modality (Haplo-SCT vs. MSDT)0.4650.265–0.8150.0080.3600.197–0.6550.001
Non-relapse mortality
 Platelet engraftment (Yes vs. no)0.0380.015–0.097< 0.0010.0480.018–0.122< 0.001
 Grades II–IV acute GVHD3.3821.481–7.7230.0042.5731.102–6.0080.029
 Transplant modality (Haplo-SCT vs. MSDT)1.0950.372–3.2180.8690.6630.213–2.0610.478
Leukemia-free survival
 Disease status (≥ CR2 vs. CR1)2.0151.238–3.2780.0051.7891.059–3.0240.030
 Diagnosis  0.013  0.021
  T-ALL2.6531.351–5.2080.0052.6961.308–5.5580.007
  PH negative B-ALL1.3570.776–2.3710.2841.3750.765–2.4720.287
  PH positive B-ALL1.0  1.0  
 Levels of pre-transplantation MRD1.3581.160–1.590< 0.0011.7471.011–3.0210.046
 Platelet engraftment (yes vs. no)0.1300.062–0.275< 0.0010.1530.067–0.352< 0.001
 Grades II–IV acute GVHD1.9911.232–3.2180.0051.7271.036–2.8790.036
 Chronic GVHD (yes vs. no)0.4740.288–0.7810.0030.4760.282–0.8030.005
 Post-transplantation MRD1.5000.955–2.3570.0781.7071.059–2.7520.028
 Transplant modality (Haplo-SCT vs. MSDT)0.5700.349–0.9330.0250.4250.252–0.7180.001
Overall survival
 Disease status (≥ CR2 vs. CR1)2.3111.404–3.8060.0012.2381.321–3.7900.003
 Diagnosis  0.015  0.005
  T-ALL2.9381.414–6.1050.0043.6021.670–7.7700.001
  PH negative B-ALL1.6310.890–2.9870.1131.9381.044–3.5960.036
  PH positive B-ALL1.0  1.0  
 Levels of pre-transplantation MRD1.3121.107–1.5550.0021.2020.975–1.4820.085
 Platelet engraftment (yes vs. no)0.0770.036–0.169< 0.0010.0830.034–0.199< 0.001
 Grades II–IV acute GVHD2.5551.559–4.185< 0.0012.4261.442–4.0820.001
 Chronic GVHD (yes vs. no)0.4820.292–0.7940.0040.4690.269–0.8200.008
 Post-transplantation MRD1.4380.915–2.2590.1161.6490.990–2.7460.055
 Transplant modality (Haplo-SCT vs. MSDT)0.5840.348–0.9800.0420.3950.225–0.6950.001
  1. All variables were first included in the univariate analysis; only variables with P<0.1 and the forced variable (transplant modality) were included in the Cox proportional hazards model with time-dependent variables
  2. HR hazard ratio, CI confidence interval, MRD minimal residual disease, CR complete remission, Haplo-SCT haploidentical stem cell transplantation, MSDT human leukocyte antigen-matched sibling donor transplantation, ALL acute lymphoblastic leukemia, GVHD graft-versus-host disease